Skip to content

HemoGenyx

Breakthrough therapies for the treatment of blood diseases.

From
London, UK

Founded
2012

Cohort Year: Y1 (2015)
Status: Active
HQ: London, UK

Y1 (2015) Life Sciences EXIT

Hemogenyx Pharmaceuticals PLC is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals plc’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia, and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

HemoGenyx Pitch at 43North Finals 2015

Founders

Vladislav Sandler